Loading
Pivekimab sunirine is an antibody-drug conjugate against CD123, approved in 2026 for blastic plasmacytoid dendritic cell neoplasm as the second targeted drug for this rare cancer.
Pivekimab sunirine is an antibody-drug conjugate: an anti-CD123 antibody joined by a cleavable linker to an indolinobenzodiazepine pseudodimer (IGN) payload that alkylates DNA without cross-linking. CD123 is highly expressed on blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive haematological cancer. The CADENZA pivotal study in untreated BPDCN showed high complete response rates with fewer capillary-leak events than tagraxofusp, the first CD123-directed drug, and the FDA approved it in May 2026, making it the second targeted therapy for this disease. It is also being studied in CD123-positive AML in combination with azacitidine and venetoclax. Whether it improves long-term survival and how it should be sequenced with transplant remain open. For a newcomer, it delivers a DNA-damaging payload directly to cells that carry the CD123 marker.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Anti-CD123 antibody conjugated via a cleavable linker to an indolinobenzodiazepine pseudodimer (IGN) that alkylates DNA without cross-linking. Connects to CD123.
1.Pivekimab sunirine's antibody arm binds CD123 on the surface of the cancer cell.
Sources: NICE search: pivekimab sunirine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-11-30 | ImmunoGen to AbbVie (incl. ImmunoGen, Capstan) Mirvetuximab soravtansine (Elahere) and pivekimab sunirine | Acquisition | not disclosed | $10.1bn | source |
Compare all products across the US, EU, UK, Japan, China and Australia →
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy source
| Region | Year | Indication |
|---|---|---|
| US | 2026 | Blastic plasmacytoid dendritic cell neoplasm |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pivekimab sunirine" OR ABSTRACT:"Pivekimab sunirine" OR TITLE:"Decnupaz" OR ABSTRACT:"Decnupaz" OR TITLE:"IMGN632" OR ABSTRACT:"IMGN632") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pivekimab sunirine, not a curated reading list.
Shares CD123, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Acute myeloid leukaemia.
Shares CD123, Acute myeloid leukaemia, Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).